Bioxytran, Inc. (BIXT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bioxytran, Inc. (BIXT) with AI Score 46/100 (Weak). Bioxytran, Inc. is a clinical-stage pharmaceutical company focused on developing drugs for hypoxic conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Bioxytran, Inc. (BIXT) Healthcare & Pipeline Overview
Bioxytran, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for hypoxia and related conditions. Their focus on oxygen-carrying small molecules and galectin-1 inhibitors positions them within the evolving landscape of targeted therapies for neurological and infectious diseases, albeit with significant developmental and regulatory hurdles.
Investment Thesis
Bioxytran's investment thesis hinges on the successful development and commercialization of BXT-25 and ProLectin-Rx. BXT-25 addresses a critical need in treating hypoxic conditions, particularly in stroke patients and wound healing, representing a significant market opportunity if clinical trials demonstrate efficacy and safety. The development of ProLectin-Rx as a COVID-19 treatment offers additional potential revenue streams, although the evolving landscape of COVID-19 therapeutics presents challenges. Key value drivers include positive clinical trial results, strategic partnerships, and regulatory approvals. However, the company faces significant risks, including the need for substantial capital to fund clinical trials, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $0.00B and a negative P/E ratio of -1.32, the company's valuation is highly speculative and dependent on future success.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead drug candidate BXT-25 targets hypoxic conditions in the brain resulting from stroke.
- Developing ProLectin-Rx for treatment of mild to moderate cases of Covid-19.
- The company has a small team of 3 employees.
- Market capitalization is $0.00B, reflecting its early-stage nature.
- P/E ratio is -1.32, indicating current lack of profitability.
Competitors & Peers
Strengths
- Novel drug candidates targeting unmet medical needs.
- Focus on hypoxia, a critical factor in various diseases.
- Potential for significant market share if drugs are approved.
- Proprietary technology platform.
Weaknesses
- Early-stage clinical development with high risk of failure.
- Limited financial resources.
- Small team with limited expertise.
- Dependence on successful clinical trials and regulatory approvals.
Catalysts
- Upcoming: Clinical trial results for BXT-25 in stroke patients.
- Upcoming: Clinical trial results for BXT-25 in wound healing.
- Upcoming: Clinical trial results for ProLectin-Rx in COVID-19 patients.
- Upcoming: Potential strategic partnerships with larger pharmaceutical companies.
- Ongoing: Regulatory submissions and approvals for BXT-25 and ProLectin-Rx.
Risks
- Potential: Failure of clinical trials for BXT-25 or ProLectin-Rx.
- Potential: Regulatory delays or rejection of drug applications.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources to fund clinical development.
- Ongoing: Dependence on key personnel and intellectual property.
Growth Opportunities
- BXT-25 for Stroke Treatment: The market for stroke therapeutics is projected to reach billions of dollars by 2028, driven by an aging population and increasing stroke incidence. BXT-25's potential to improve oxygen delivery to the brain during a stroke could offer a significant advantage over existing treatments. Successful completion of clinical trials and FDA approval could lead to substantial revenue generation, with a potential market entry timeline of 3-5 years.
- BXT-25 for Wound Healing: Hypoxic conditions in wounds can lead to necrosis and delayed healing. BXT-25's oxygen-carrying capabilities could accelerate wound healing and prevent complications. The market for wound care products is substantial and growing, presenting a significant opportunity for Bioxytran. Clinical trials demonstrating efficacy in wound healing could open up a new revenue stream within 2-4 years.
- ProLectin-Rx for COVID-19 Treatment: While the COVID-19 therapeutics market is becoming crowded, there remains a need for effective treatments for mild to moderate cases. ProLectin-Rx's mechanism of action, targeting galectin-1, could offer a unique approach to treating COVID-19. Positive clinical trial results and regulatory approval could lead to a share of this market, with a potential timeline of 1-3 years.
- Strategic Partnerships: Bioxytran could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to funding, expertise, and distribution networks, increasing the likelihood of success. Securing a partnership within the next 1-2 years would significantly de-risk the company's development pipeline.
- Expansion into Other Hypoxic Conditions: Bioxytran's technology platform could be expanded to address other hypoxic conditions beyond stroke and wound healing. This could include conditions such as chronic obstructive pulmonary disease (COPD) and peripheral artery disease (PAD). Exploring these additional indications could broaden the company's market opportunity and create new revenue streams within 3-5 years.
Opportunities
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new indications for BXT-25.
- Government funding for COVID-19 therapeutics.
- Growing market for stroke and wound care treatments.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Failure of clinical trials.
- Inability to secure funding.
Competitive Advantages
- Proprietary drug formulations (BXT-25 and ProLectin-Rx).
- Patent protection on its drug candidates.
- Specialized knowledge in oxygen-carrying molecules and galectin-1 inhibition.
- First-mover advantage in targeting specific hypoxic conditions with BXT-25.
About BIXT
Bioxytran, Inc., founded in 2008 and headquartered in Newton, Massachusetts, is a clinical-stage pharmaceutical company dedicated to addressing hypoxia, a condition characterized by insufficient oxygen supply to tissues. The company's primary focus is the development, manufacture, and commercialization of therapeutic drugs designed to improve oxygen delivery and combat related complications. Their lead drug candidate, BXT-25, is an oxygen-carrying small molecule composed of bovine hemoglobin stabilized with a co-polymer. This drug is being developed for the treatment of hypoxic conditions in the brain resulting from stroke, as well as for hypoxic conditions in wounds to prevent necrosis and promote healing. In addition to BXT-25, Bioxytran is also developing ProLectin-Rx, a polysaccharide derived from pectin. ProLectin-Rx is designed to bind to and block the activity of galectin-1, a type of galectin implicated in the pathogenesis of COVID-19. The company aims to develop ProLectin-Rx as a treatment for mild to moderate cases of COVID-19. Bioxytran operates with a small team of three employees, reflecting its stage as a development-focused company. The company's strategy involves advancing its drug candidates through clinical trials and seeking regulatory approvals to bring these therapies to market.
What They Do
- Develops BXT-25, an oxygen-carrying molecule for treating hypoxia in the brain after stroke.
- Develops BXT-25 for treating hypoxic conditions in wounds to prevent necrosis.
- Creates ProLectin-Rx, a drug to treat mild to moderate cases of COVID-19.
- Focuses on manufacturing and commercializing therapeutic drugs.
- Aims to improve oxygen delivery to tissues affected by hypoxia.
- Targets galectin-1 with ProLectin-Rx to block its activity in COVID-19 patients.
Business Model
- Develops pharmaceutical products targeting specific diseases.
- Conducts clinical trials to prove the safety and efficacy of its drugs.
- Seeks regulatory approval from agencies like the FDA.
- Plans to commercialize approved drugs through partnerships or direct sales.
Industry Context
Bioxytran operates within the biotechnology industry, a sector characterized by high risk and high reward. The market for stroke therapeutics is substantial, driven by the increasing prevalence of stroke and the limited treatment options available. The COVID-19 therapeutics market is rapidly evolving, with numerous companies developing antiviral drugs and vaccines. Competition in both markets is intense, with established pharmaceutical companies and other biotechnology firms vying for market share. Bioxytran's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.
Key Customers
- Hospitals and medical centers treating stroke patients.
- Wound care clinics and specialists.
- Patients suffering from mild to moderate COVID-19.
- Pharmaceutical companies interested in licensing or acquiring novel drugs.
Financials
Chart & Info
Bioxytran, Inc. (BIXT) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIXT.
Price Targets
Wall Street price target analysis for BIXT.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIXT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Platt
CEO
David Platt serves as the CEO of Bioxytran, Inc., managing a small team focused on developing novel therapeutics. Information regarding his detailed career history, educational background, and specific credentials is not available in the provided data. However, as CEO, he is responsible for the strategic direction and operational execution of the company's goals.
Track Record: Due to the limited information available, it is difficult to assess David Platt's specific track record at Bioxytran. Key milestones and strategic decisions under his leadership are not detailed in the provided data. The company's progress in advancing its drug candidates through clinical trials will be a critical indicator of his leadership effectiveness.
BIXT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bioxytran may not meet the minimum financial or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to less stringent listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price manipulation.
- Higher risk of fraud or mismanagement compared to listed companies.
- OTC Other tier companies may have difficulty raising capital.
- Potential for delisting or trading suspensions.
- Verify the company's registration with the SEC.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Active development of drug candidates (BXT-25 and ProLectin-Rx).
- Focus on addressing unmet medical needs.
- Presence of patent filings or intellectual property protection.
- Company has been in operation since 2008.
- Company headquarters in Newton, Massachusetts.
What Investors Ask About Bioxytran, Inc. (BIXT)
What does Bioxytran, Inc. do?
Bioxytran, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing therapeutic drugs to treat hypoxia, a condition where the body's tissues don't receive enough oxygen. Their lead drug candidate, BXT-25, is designed to improve oxygen delivery to the brain after a stroke and to promote wound healing. Additionally, they are developing ProLectin-Rx as a treatment for mild to moderate cases of COVID-19 by targeting galectin-1, a protein involved in the disease's progression. The company aims to address unmet medical needs in these areas through innovative drug development.
What do analysts say about BIXT stock?
As of March 16, 2026, there is no available analyst coverage or consensus on Bioxytran (BIXT) stock. Given its market cap of $0.00B and negative P/E ratio, the company is considered a high-risk, high-reward investment. Its valuation is primarily based on the potential success of its drug candidates in clinical trials and subsequent regulatory approvals. Investors should conduct thorough due diligence and consider the significant risks associated with investing in early-stage biotechnology companies before making any investment decisions.
What are the main risks for BIXT?
Bioxytran faces several key risks inherent to its stage and industry. The primary risk is the potential failure of its drug candidates, BXT-25 and ProLectin-Rx, in clinical trials. Clinical trials are costly and have a high rate of failure, which could significantly impact the company's valuation. Regulatory risks are also substantial, as the FDA approval process is complex and time-consuming. Competition from larger pharmaceutical companies with greater resources poses another threat. Finally, the company's limited financial resources and small team create operational risks and dependence on securing additional funding.
What are the key factors to evaluate for BIXT?
Bioxytran, Inc. (BIXT) currently holds an AI score of 46/100, indicating low score. Key strength: Novel drug candidates targeting unmet medical needs.. Primary risk to monitor: Potential: Failure of clinical trials for BXT-25 or ProLectin-Rx.. This is not financial advice.
How frequently does BIXT data refresh on this page?
BIXT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIXT's recent stock price performance?
Recent price movement in Bioxytran, Inc. (BIXT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel drug candidates targeting unmet medical needs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIXT overvalued or undervalued right now?
Determining whether Bioxytran, Inc. (BIXT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIXT?
Before investing in Bioxytran, Inc. (BIXT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.
- AI analysis pending for BIXT.